Open-house drug discount agreements
Titre original de l'avis
Germany – Pharmaceutical products – Arzneimittelrabattverträge gem. § 130a Abs. 8 SGB V im Rahmen von Open-House-Verfahren
Score d'opportunité
Pourquoi ce score ?
Opportunité
50 / 100
Complexité
15 / 100
Facteurs de risque
No estimated contract value or framework maximum value disclosed; bidders cannot assess potential revenue.
Only the XML notice was analyzed; full procurement documents (agreement terms, self-declaration forms) have not been re...
Analyse approfondie du portefeuille
Utilise:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Aperçu
Moderate opportunityFaits clés
- Supplies contract
- 2 lots
- Duration until Jul 2027
- Supply of pharmaceutical products (Nilotinib and Diclofenac) under non-exclusive discount agreements.
- Framework agreements with IKK classic, running from August 1, 2025 to July 31, 2027.
Afficher le résumé complet
Open House procedure by IKK classic for non-exclusive pharmaceutical discount agreements (Rabattverträge) under §130a SGB V for two active substances (Nilotinib and Diclofenac). Eligible pharmaceutical companies can join at any time from August 1, 2025, to July 31, 2027, subject to submission deadlines. No estimated values or award criteria provided. Submission via email or postal mail; electronic submission not allowed. Eligibility limited to pharmaceutical entrepreneurs per §4 Abs. 18 AMG.
Risques
No estimated contract value or framework maximum value disclosed; bidders cannot assess potential revenue.
Only the XML notice was analyzed; full procurement documents (agreement terms, self-declaration forms) have not been re...
L'analyse peut être incomplète
Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.
Exigences clés
Eligibility
- Only pharmaceutical entrepreneurs as defined in §4 Abs. 18 AMG are eligible (including consortia of such entrepreneurs).
Administrative
- Submission of signed contract, all required declarations and documents via email or postal mail; electronic submission not allowed.
- Documents must be submitted by the 5th of a month for contract start on the 1st of the following month (or later date if after the 5th).
Les exigences peuvent être incomplètes.
Acheteur
Lots (2)
LOT-0001
Nilotinib
Nilotinib, allowed only for administration dispersed in applesauce, ATC Code L01AE03. Framework agreement for supply of pharmaceuticals. Performance in DEU, region DED21.
Localisation
Durée
Catégorie
Date limite
Détails des critères
Nilotinib
nur mit zulässiger Verabreichung dispergiert in Apfelmus
ATC-Code: L01AE03
Note sur la valeur
Afficher les données TED originales
Titre original du lot
Nilotinib; nur mit zulässiger Verabreichung dispergiert in Apfelmus; ATC-Code: L01AE03
Description TED originale
Nilotinib; nur mit zulässiger Verabreichung dispergiert in Apfelmus; ATC-Code: L01AE03
LOT-0002
Diclofenac
Diclofenac retard capsules and tablets, strengths 75 mg (pack sizes 30, N2, N3) and 150 mg (pack sizes 10, N1), ATC Code M01AB05. Framework agreement for supply of pharmaceuticals. Performance in DEU, region DED21.
Localisation
Durée
Catégorie
Date limite
Détails des critères
Diclofenac
Retardkapseln, Retardtabletten
ATC-Code: M01AB05
Wirkstärke 75 mg mit Packungsgrößen: 30, N2, N3
Wirkstärke 150 mg mit Packungsgrößen 10, N1
Note sur la valeur
Afficher les données TED originales
Titre original du lot
Diclofenac; Retardkapseln, Retardtabletten; ATC-Code: M01AB05; Wirkstärke 75 mg mit Packungsgrößen: 30, N2, N3; Wirkstärke 150 mg mit Packungsgrößen 10, N1
Description TED originale
Diclofenac; Retardkapseln, Retardtabletten; ATC-Code: M01AB05; Wirkstärke 75 mg mit Packungsgrößen: 30, N2, N3; Wirkstärke 150 mg mit Packungsgrößen 10, N1
Détails de la procédure
- Date de publication
- 19 Jun 2025
- Langues
- German
Métadonnées de référence
- Base juridique
- 32014L0024
Identifiants de référence
- ID de l'appel d'offres
- 400529-2025
Documents (1)
Appels d'offres similaires
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Score d'opportunité
Pourquoi ce score ?
Opportunité
50 / 100
Complexité
15 / 100
Facteurs de risque
No estimated contract value or framework maximum value disclosed; bidders cannot assess potential revenue.
Only the XML notice was analyzed; full procurement documents (agreement terms, self-declaration forms) have not been re...
Analyse approfondie du portefeuille
Utilise:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications